<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36400086</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2214-109X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Global health</Title><ISOAbbreviation>Lancet Glob Health</ISOAbbreviation></Journal><ArticleTitle>Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021.</ArticleTitle><Pagination><StartPage>e1807</StartPage><EndPage>e1814</EndPage><MedlinePgn>e1807-e1814</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2214-109X(22)00412-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2214-109X(22)00412-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Novel oral poliovirus vaccine type 2 (nOPV2) was used to control an outbreak of type 2 circulating vaccine derived poliovirus (cVDPV2) in Tajikistan, in 2021. We measured seroconversion and seroprevalence of type 2 polio antibodies in children who were reported to have received two doses of nOPV2 in outbreak response campaigns.</AbstractText><AbstractText Label="METHODS">In this community serosurvey, children born after Jan 1, 2016 were enrolled from seven districts in Tajikistan. Dried blood spot cards were collected before nOPV2 campaigns and after the first and second rounds of the campaigns and were sent to the Centers for Disease Control and Prevention (Atlanta, GA, USA) for microneutralisation assay to determine presence of polio antibodies. The primary endpoint was to assess change in seroprevalence and seroconversion against poliovirus serotype 2 after one and two doses of nOPV2.</AbstractText><AbstractText Label="FINDINGS">228 (97%) of 236 enrolled children were included in the analysis. The type 2 antibody seroprevalence was 26% (53/204; 95% CI 20 to 33) before nOPV2, 77% (161/210; 70 to 82) after one dose of nOPV2, and 83% (174/209; 77 to 88) after two doses of nOPV2. The increase in seroprevalence was statistically significant between baseline and after one nOPV2 dose (51 percentage points [42 to 59], p&lt;0·0001), but not between the first and second doses (6 percentage points [-2 to 15], p=0·12). Seroconversion from the first nOPV2 dose, 67% (89/132; 59 to 75), was significantly greater than that from the second nOPV2 dose, 44% (20/45; 30 to 60; χ<sup>2</sup> p=0·010). Total seroconversion after two nOPV2 doses was 77% (101/132; 68 to 83).</AbstractText><AbstractText Label="INTERPRETATION">Our study demonstrated strong immune responses following nOPV2 outbreak response campaigns in Tajikistan. Our results support previous clinical trial data on the generation of poliovirus type 2 immunity by nOPV2 and provide evidence that nOPV2 can be appropriate for the cVDPV2 outbreak response. The licensure and WHO prequalification of nOPV2 should be accelerated to facilitate wider use of the vaccine.</AbstractText><AbstractText Label="FUNDING">World Health Organization, Centers for Disease Control and Prevention, and Rotary International.</AbstractText><CopyrightInformation>Copyright © 2022 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirzoev</LastName><ForeName>Azamdzhon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Postgraduate Education in Health, Dushanbe, Tajikistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Grace R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland. Electronic address: mackling@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yiting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainou</LastName><ForeName>Bernardo A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadykova</LastName><ForeName>Umeda</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>World Health Organization, Country Office, Dushanbe, Tajikistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsavszky</LastName><ForeName>Victor Stefan</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>World Health Organization, Country Office, Dushanbe, Tajikistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huseynov</LastName><ForeName>Shahin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>World Health Organization, Regional Office for Europe, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruziev</LastName><ForeName>Murodali</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Preventive Medicine, Dushanbe, Tajikistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saidzoda</LastName><ForeName>Faizali</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Republican Center for Immuno-prophylaxis, Dushanbe, Tajikistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobokhonova</LastName><ForeName>Mahtob</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Republican Center for Immuno-prophylaxis, Dushanbe, Tajikistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Glob Health</MedlineTA><NlmUniqueID>101613665</NlmUniqueID><ISSNLinking>2214-109X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Glob Health. 2022 Dec;10(12):e1697-e1698. doi: 10.1016/S2214-109X(22)00452-1</RefSource><PMID Version="1">36400075</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013620" MajorTopicYN="N" Type="Geographic">Tajikistan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36400086</ArticleId><ArticleId IdType="pmc">PMC9681660</ArticleId><ArticleId IdType="doi">10.1016/S2214-109X(22)00412-0</ArticleId><ArticleId IdType="pii">S2214-109X(22)00412-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  Polio AFP case count. 2022. https://extranet.who.int/polis/public/CaseCount.aspx</Citation></Reference><Reference><Citation>Burns CC, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol. 2013;87:4907–4922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine. 2009;27:2649–2652.</Citation><ArticleIdList><ArticleId IdType="pubmed">19428874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker EP, Molodecky NA, Pons-Salort M, O'Reilly KM, Grassly NC. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Rev Vaccines. 2015;14:1113–1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4673562</ArticleId><ArticleId IdType="pubmed">26159938</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, O'Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral poliovirus vaccine. Science. 2020;368:401–405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G, Peak C, Eisenhawer M, et al. Enabling accelerated vaccine roll-out for public health emergencies of international concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience. Vaccine. 2022 doi: 10.1016/j.vaccine.2022.02.050. published online March 17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736–751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt JL, Campagnoli R, Vincent A, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Novel Oral Polio Vaccine type 2 (nOPV2) granted EUL recommendation. 2021. https://polioeradication.org/news-post/novel-oral-polio-vaccine-type-2-nopv2-granted-interim-emergency-use-listing-recommendation/</Citation></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148–158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Coster I, Bandyopadhyay AS, et al. Poliopolis: pushing boundaries of scientific innovations for disease eradication. Future Microbiol. 2019;14:1321–1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9186300</ArticleId><ArticleId IdType="pubmed">31482728</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I, Leroux-Roels I, Bandyopadhyay AS, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397:39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, Mercer L, Gast C, et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines. 2022;7:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8837630</ArticleId><ArticleId IdType="pubmed">35149714</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor P, Huseynov S, Nielsen CF, et al. Notes from the field: readiness for use of type 2 novel oral poliovirus vaccine in response to a type 2 circulating vaccine-derived poliovirus outbreak - Tajikistan, 2020-2021. MMWR Morb Mortal Wkly Rep. 2022;71:361–362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893333</ArticleId><ArticleId IdType="pubmed">35239638</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Circulating vaccine-derived poliovirus type 2 detected in Tajikistan. 2021. https://www.euro.who.int/en/countries/tajikistan/news/news/2021/3/circulating-vaccine-derived-poliovirus-type-2-detected-in-tajikistan</Citation></Reference><Reference><Citation>WHO  WHO/UNICEF estimates of national immunization coverage. 2021. https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/global-monitoring/immunization-coverage/who-unicef-estimates-of-national-immunization-coverage</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145–176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H, Nie L, Chen Y, Huang Y, Sun W. Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: methods for the absolute risk difference and relative risk. Stat Methods Med Res. 2012;21:621–633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348438</ArticleId><ArticleId IdType="pubmed">21177306</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Zaman K, Estívariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine. 2015;33:6816–6822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10423714</ArticleId><ArticleId IdType="pubmed">26476367</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368:416–424.</Citation><ArticleIdList><ArticleId IdType="pubmed">23363495</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis. 2014;210(suppl 1):S439–S446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197908</ArticleId><ArticleId IdType="pubmed">24634499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Modlin JF, Wenger J, Gast C. Immunogenicity of new primary immunization schedules with inactivated poliovirus vaccine and bivalent oral polio vaccine for the polio endgame: a review. Clin Infect Dis. 2018;67(suppl 1):S35–S41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206125</ArticleId><ArticleId IdType="pubmed">30376081</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158–169.</Citation><ArticleIdList><ArticleId IdType="pubmed">27212429</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleem AF, Mach O, Yousafzai MT, et al. Immunogenicity of different routine poliovirus vaccination schedules: a randomized, controlled trial in Karachi, Pakistan. J Infect Dis. 2018;217:443–450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191618</ArticleId><ArticleId IdType="pubmed">29126173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X, Clemens R, Leroux-Roels G, et al. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2016;16:321–330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108810</ArticleId><ArticleId IdType="pubmed">26719058</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13:926–939.</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach O, Verma H, Khandait DW, et al. Prevalence of asymptomatic poliovirus infection in older children and adults in northern India: analysis of contact and enhanced community surveillance, 2009. J Infect Dis. 2014;210(suppl 1):S252–S258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4663665</ArticleId><ArticleId IdType="pubmed">25316843</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>